• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Petra Acquisition, Inc. (Amendment)

    1/11/22 3:34:57 PM ET
    $PAIC
    Business Services
    Finance
    Get the next $PAIC alert in real time by email
    SC 13G/A 1 lf_sc13gz.htm SCHEDULE 13G/A Schedule 13G

     

    OMB APPROVAL

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    OMB Number:3235-0145 

    Expires:Febuary 28, 2009 

    Estimated average burden
    hours per response ....10.4

     

     

    SCHEDULE 13G

    Under the Securities and Exchange Act of 1934

    (Amendment No.       2          )*

     

    Petra Acquisition, Inc.

    (Name of Issuer)

     

    Common stock. $0.001 par value

    (Title of Class of Securities)

     

    716421102

    (CUSIP Number)

     

     

    January 10, 2022

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    o  Rule 13d-1(b)

    ý  Rule 13d-1(c)

    o  Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


    1


     

    CUSIP No.   716421102

    1.Names of Reporting Persons. 

    I.R.S. Identification Nos. of above persons (entities only). 

    Feis Equities LLC 

    2.Check the Appropriate Box if a Member of a Group 

    (a)o 

    (b)o 

    3.SEC Use Only 

    4.Citizenship or Place of OrganizationState of Illinois 

    Number of Shares Beneficially Owned by Each Reporting Person With

    5.Sole Voting Power0 

    6.Shared Voting Power0 

    7.Sole Dispositive Power0 

    8.Shared Dispositive Power0 

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 

    0 

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)      o 

    11.Percent of Class Represented by Amount in Row (9) 

    0.00% 

    12.Type of Reporting Person (See Instructions) 

    OO-Limited Liability Company 


    2


     

    CUSIP No. 716421102

    1.Names of Reporting Persons. 

    I.R.S. Identification Nos. of above persons (entities only). 

    Lawrence M. Feis 

    2.Check the Appropriate Box if a Member of a Group 

    (a)o 

    (b)o 

    3.SEC Use Only 

    4.Citizenship or Place of OrganizationU.S.A. 

    Number of Shares Beneficially Owned by Each Reporting Person With

    5.Sole Voting Power0 

    6.Shared Voting Power0 

    7.Sole Dispositive Power0 

    8.Shared Dispositive Power0 

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 

    0 

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)      o 

    11.Percent of Class Represented by Amount in Row (9)  

    0.00% 

    12.Type of Reporting Person (See Instructions) 

    IN 


    3


     

    Item 1.

    The name and address of the principal executive offices of the Issuer are:

    Petra Acquisition, Inc.

    5 West 21st Street

    New York, NY  10010

    Item 2.

    This statement on Schedule 13G is being filed by:

    (a) Name of Person Filing 

     

    (i)Feis Equities LLC 

    (ii)Lawrence M. Feis 

     

     

     

     

     

    (b)Address: 

    The address of the business office of each of the Reporting Persons is:

     

    20 North Wacker Drive

    Suite 2115

    Chicago, Illinois  60606

     

     

     

     

     

    (c)Citizenship/Place: 

    Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated hereto by reference for each Reporting Person.

     

    (d)Title of Class of Securities: 

    Common stock, $0.001 par value

     

    (e)CUSIP Number: 

     

     

     

    716421102

     


    4


    Item 3.  If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    (a)oBroker or dealer registered under section 15 of the Act (15 U.S.C. 78o). 

    (b)oBank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). 

    (c)oInsurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). 

    (d)oInvestment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8). 

    (e)oAn investment adviser in accordance with §240.13d-1(b)(1)(ii)(E); 

    (f)oAn employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F); 

    (g)oA parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G); 

    (h)oA savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); 

    (i)oA church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); 

    (j)oGroup, in accordance with §240.13d-1(b)(1)(ii)(J). 

    Item 4.  Ownership

     

    The information required by Items 4(a)-(c) is set forth in Rows 5-11 of the cover page for each Reporting Person and incorporated by reference herein.

     

    The percentage set forth in row 11 of the cover page for each Reporting Person is based on 9,097,689 shares of common stock outstanding as of October 29, 2021, as reported by the Issuer in its Quarterly Report on Form 10-Q/A for the quarter ended September 30, 2021, filed with the Securities and Exchange Commission on October 29, 2021.


    5


     

    Item 5.  Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following  ý

    Item 6.  Ownership of More than Five Percent on Behalf of Another Person

    Not applicable.

    Item 7.  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

    Not applicable.

    Item 8.  Identification and Classification of Members of the Group

    Not applicable.

    Item 9.  Notice of Dissolution of Group

    Not applicable.

    Item 10.  Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    6


    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date:January 11, 2022 

     

     

     

     

    Date:January 11, 2022 

     

    FEIS EQUITIES LLC

    By:/s/ Lawrence M. Feis 

                Managing Member LLC

     

     

    LAWRENCE M. FEIS

    By:/s/ Lawrence M. Feis 

     


    7


     

     

    EXHIBIT INDEX

     

    Ex.

     

    Page No.

     

     

     

    A

    Joint Filing Agreement

    9


    8


     

    JOINT FILING AGREEMENT

     

    The undersigned hereby agree that the statement on Schedule 13G with respect to the Common stock of Petra Acquisition, Inc. dated as of January 11, 2022 is, and any amendments thereto (including amendments on Schedule 13D) signed by each of the undersigned shall be filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.

     

    FEIS EQUITIES LLC 

    By:/s/ Lawrence M. Feis 

    Managing Member LLC 

     

     

    LAWRENCE M. FEIS 

    By:/s/ Lawrence M. Feis 

     

    Date:  January 11, 2022


    9

    Get the next $PAIC alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $PAIC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PAIC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Revelation Biosciences Inc. Receives Approval to Initiate Phase 2b Viral Challenge Study of REVTx 99, an Experimental Prophylactic Treatment for the Prevention of Respiratory Viral Infections

      - Phase 2b study will investigate the efficacy of REVTx-99 on viral load and patient-reported flu symptoms- - Top-line data anticipated in the second quarter of 2022 - SAN DIEGO, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (Revelation), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, announced today it has received approval from the Federal Agency for Medicines and Health Products (FAMHP) and the local Committee of Medical Ethics in Belgium to conduct a Phase 2b influenza viral challenge study. The Phase 2b, randomized, double-blind, influenza viral challenge study (RV

      9/28/21 9:00:00 AM ET
      $PAIC
      Business Services
      Finance
    • Revelation Biosciences, Inc., a Life Sciences Company Developing Therapeutics and Diagnostics for Respiratory Viral Infections, Including COVID-19, to Become Publicly Traded Through a Merger with Petra Acquisition, Inc.

      Revelation's lead product candidate REVTx-99 has potential, through innate immune system stimulation, to broadly prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2 including its variants, influenza A and B, parainfluenza, rhinovirus, and respiratory syncytial virus (RSV) Combined company expected to have a post-transaction pro forma total enterprise value of approximately $128 million Merger expected to close in Q4 2021, and combined company will be listed on NASDAQ under the ticker symbol "REVB" Revelation and Petra Acquisition will host a joint investor conference call and webcast to discuss the proposed transaction on August 30, 2021 at 4:30 p.m

      8/30/21 6:00:00 AM ET
      $PAIC
      Business Services
      Finance
    • PETRA ACQUISITION, INC. RECEIVES EXPECTED NASDAQ NOTIFICATION REGARDING DELAYED FORM 10-Q

      New York, NY, June 01, 2021 (GLOBE NEWSWIRE) -- Petra Acquisition, Inc. (NASDAQ:PAIC) (the "Company"), a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities, announced that on May 28, 2021, it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq") advising that because the Company failed to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2021 (the "Form 10-Q"), the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule"). Nasdaq has inform

      6/1/21 4:30:00 PM ET
      $PAIC
      Business Services
      Finance

    $PAIC
    SEC Filings

    See more
    • Petra Acquisition, Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits, Unregistered Sales of Equity Securities, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Change in Shell Company Status

      8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)

      1/14/22 4:28:56 PM ET
      $PAIC
      Business Services
      Finance
    • Petra Acquisition, Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)

      1/13/22 3:53:16 PM ET
      $PAIC
      Business Services
      Finance
    • Petra Acquisition, Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)

      1/12/22 4:49:37 PM ET
      $PAIC
      Business Services
      Finance

    $PAIC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Feis Lawrence disposed of $7,465,890 worth of shares (731,950 units at $10.20)

      4 - Petra Acquisition Inc. (0001810560) (Issuer)

      1/11/22 3:59:54 PM ET
      $PAIC
      Business Services
      Finance
    • SEC Form 3: New insider Feis Lawrence claimed ownership of 746,491 shares

      3 - Petra Acquisition Inc. (0001810560) (Issuer)

      11/2/21 2:39:14 PM ET
      $PAIC
      Business Services
      Finance
    • SEC Form 4: Glazer Capital, Llc sold $6,597,824 worth of Common stock (654,546 units at $10.08)

      4 - Petra Acquisition Inc. (0001810560) (Issuer)

      9/23/21 4:21:06 PM ET
      $PAIC
      Business Services
      Finance

    $PAIC
    Financials

    Live finance-specific insights

    See more
    • Revelation Biosciences, Inc., a Life Sciences Company Developing Therapeutics and Diagnostics for Respiratory Viral Infections, Including COVID-19, to Become Publicly Traded Through a Merger with Petra Acquisition, Inc.

      Revelation's lead product candidate REVTx-99 has potential, through innate immune system stimulation, to broadly prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2 including its variants, influenza A and B, parainfluenza, rhinovirus, and respiratory syncytial virus (RSV) Combined company expected to have a post-transaction pro forma total enterprise value of approximately $128 million Merger expected to close in Q4 2021, and combined company will be listed on NASDAQ under the ticker symbol "REVB" Revelation and Petra Acquisition will host a joint investor conference call and webcast to discuss the proposed transaction on August 30, 2021 at 4:30 p.m

      8/30/21 6:00:00 AM ET
      $PAIC
      Business Services
      Finance

    $PAIC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Petra Acquisition, Inc. (Amendment)

      SC 13G/A - Petra Acquisition Inc. (0001810560) (Subject)

      1/11/22 3:34:57 PM ET
      $PAIC
      Business Services
      Finance
    • SEC Form SC 13G/A filed by Petra Acquisition, Inc. (Amendment)

      SC 13G/A - Petra Acquisition Inc. (0001810560) (Subject)

      10/12/21 4:02:40 PM ET
      $PAIC
      Business Services
      Finance
    • SEC Form SC 13G/A filed by Petra Acquisition, Inc. (Amendment)

      SC 13G/A - Petra Acquisition Inc. (0001810560) (Subject)

      10/12/21 10:33:03 AM ET
      $PAIC
      Business Services
      Finance